Can we use hydroxychloroquine to treat COVID-19 now?

Chen, Jun; Liu, Danping; Yin, Lin; Zhang, Lijun; Lu, Hongzhou

Chen, Jun; Liu, Danping; Yin, Lin; Zhang, Lijun; Lu, Hongzhou.

Chen J; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Liu D; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Yin L; Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Zhang L; Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Lu H; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China. Electronic address: luhongzhou@fudan.edu.cn.

Int J Antimicrob Agents ; 57(1): 106173, 2021 Jan.

Article in English | MEDLINE | ID: covidwho-1065125

Subject(s)

Antiviral Agents/therapeutic use; Azithromycin/therapeutic use; COVID-19 Drug Treatment; Hydroxychloroquine/therapeutic use; SARS-CoV-2/pathogenicity; Anti-Bacterial Agents/therapeutic use; Antimalarials/therapeutic use; COVID-19/virology; Clinical Trials as Topic; Drug Combinations; Drug Repositioning; Humans; Indoles/therapeutic use; Interferon-alpha/therapeutic use; Lopinavir/therapeutic use; Ritonavir/therapeutic use; Uncertainty

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Azithromycin / SARS-CoV-2 / COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2021 Document Type: Article Affiliation country: J.ijantimicag.2020.106173

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google